Results 71 to 80 of about 24,654 (177)

Small‐Molecule Kinase Inhibitors Modulating Circadian Rhythms

open access: yesMedicinal Research Reviews, Volume 46, Issue 6, Page 1735-1752, November 2026.
ABSTRACT The circadian clock mechanism generates 24‐h rhythms crucial for regulating various physiological processes, and its dysregulation has been implicated in numerous diseases. In cells, the circadian clock operates through a transcriptional‐translational feedback loop, where phosphorylation plays a pivotal role in maintaining accurate circadian ...
Irene Castellino   +3 more
wiley   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 21, Page 6261-6290, November 2026.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11)

open access: yesBMC Cancer, 2004
Background Based on the site of breakpoint in t(9;22) (q34;q11), bcr-abl fusion in leukemia patients is associated with different types of transcript proteins.
Cano Pedro   +2 more
doaj   +1 more source

Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients

open access: yesHematology Reports, 2012
Development of resistance to imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients is mediated by different mechanisms that can be classified as BCR-ABL dependent or BCR-ABL independent pathways.
Marjanu Hikmah Elias   +7 more
doaj   +1 more source

Peritoneal Tuberculosis and Chronic Myeloid Leukaemia: A Case of Hickam's Dictum

open access: yesMedical Journal of Australia, Volume 224, Issue 11, November 2026.
ABSTRACT We report the case of a 34‐year‐old male with persistent fever, ascites, thrombocytosis and clinical deterioration despite broad‐spectrum therapy who was ultimately diagnosed with peritoneal tuberculosis and concurrent chronic myeloid leukaemia.
Zayn Al‐Timimi   +3 more
wiley   +1 more source

Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway

open access: yesMolecular Cancer, 2019
Background Long noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be aberrantly expressed in diverse human diseases including cancer.
Xuefei Wang   +9 more
doaj   +1 more source

Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism

open access: yesBMC Cancer, 2012
Background Philadelphia positive leukemias are characterized by the presence of Bcr-Abl fusion protein which exhibits an abnormal kinase activity. Selective Abl kinase inhibitors have been successfully established for the treatment of Ph (+) leukemias ...
Khateb Mamduh   +7 more
doaj   +1 more source

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia. [PDF]

open access: yesPLoS One, 2022
Maletzke S   +8 more
europepmc   +1 more source

Strategic therapeutic approaches to overcome emerging dual SRC/ABL kinase inhibitors resistances in chronic phase Ph positive chronic myeloid leukemia

open access: yesAsian Journal of Medical Sciences, 2014
Chronic myeloid leukemia (CML) is a haematopoietic neoplasm with clinically distinct phases and BCR⁄ABL1 oncogene. Imatinib mesylate, a potent inhibitor of BCR-ABL was highly effective in CML but later in-vitro derived cell line with resistance namely ...
Rajat Rana
doaj   +1 more source

Home - About - Disclaimer - Privacy